NRX Pharmaceuticals Inc. 获FDA确认:NRX-100无需提交额外非临床数据或桥接研究

美股速递
Mar 16

NRX Pharmaceuticals Inc. 宣布,美国食品药品监督管理局已正式确认,其研究性药物NRX-100的后续开发无需提交额外的非临床数据或进行桥接研究。这一决定简化了该药物的临床开发路径,有望加速其研发进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10